Home › Hemophilia B › Pennsylvania
Hemophilia B clinical trials in Pennsylvania
6 studies for Hemophilia B are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- The Childrens Hospital of Philadelphia Division of Hematology, Philadelphia
- The Childrens Hospital of Philadelphia Division of Hematology, Philadelphia
RecruitingPhase 3
Ages 18 and older · Men · Updated Oct 2, 2026 · NCT05568719A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
- Children's Hospital of Philadelphia (CHOP), Philadelphia
RecruitingPhase 1/2
Ages 2 and older · Men · Updated Sep 11, 2026 · NCT06379789Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
- Hemophilia Center of Western Pennsylvania (HCWP), Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06003387ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Children's Hospital of Philadelphia, Philadelphia
- Penn Comprehensive Hemophilia and Thrombophilia Program/Hospital of the University of Pennsylvania, Philadelphia
- St. Christopher's Hospital for Children, Philadelphia
- and 1 more
RecruitingObservational study
All ages · All sexes · Updated Aug 17, 2026 · NCT04398628A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
- Penn State Milton S Hershey Medical Center Pediatrics, Hershey
- Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program, Philadelphia
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 60 · All sexes · Updated Jul 2, 2026 · NCT06349473Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- The Feinstein Institutes for Medical Research, Philadelphia
RecruitingPhase 3
Ages 1 to 74 · Men · Updated Jul 1, 2026 · NCT05145127From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.